Literature DB >> 4053491

The pharmacokinetic and bactericidal characteristics of oral cefixime.

D C Brittain, B E Scully, T Hirose, H C Neu.   

Abstract

The pharmacokinetics of cefixime (FK 027), a broad-spectrum cephalosporin, were assessed in 12 normal subjects after single oral doses of 50, 100, 200, and 400 mg. Mean peak serum concentrations were 1.02, 1.46, 2.63, and 3.85 micrograms/ml after the four respective doses. Respective mean serum levels at 12 hours were 0.16, 0.33, 0.72, and 1.13 micrograms/ml. Volumes of distribution averaged 0.1 L/kg body weight, and the elimination t1/2 was 3 hours for all doses. The AUC was 7.01, 11.4, 22.5, and 36.4 micrograms X hr/ml for the four doses, respectively. Serum clearance averaged 0.4 mg/min/kg and mean 24-hour urinary recovery was 21%, 19%, 20%, and 16% for the four respective doses. Serum bactericidal titers at 4 hours exceeded 1:16 for Streptococcus pneumoniae, S. pyogenes, Hemophilus influenzae, and Branhamella catarrhalis. Urine bactericidal titers exceeded 1:8 for Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae resistant to the available oral cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053491     DOI: 10.1038/clpt.1985.229

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].

Authors:  F Kees; K G Naber
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  [Effectiveness and tolerance of cefixime in the treatment of acute pyelonephritis].

Authors:  L Weissbach; A Segal; K Tröster
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 4.  [Cefixime in urinary tract infections. (Specific studies and literature review)].

Authors:  K G Naber
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori.

Authors:  M R Millar; J Pike
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Penetration and bactericidal activity of cefixime in synovial fluid.

Authors:  E Somekh; L Heifetz; M Dan; F Poch; H Hafeli; A Tanai
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.

Authors:  A Kuhlwein; B A Nies
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

9.  In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.